KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,529,109 | +855.2% | 1,141,126 | +1176.0% | 0.00% | – |
| Q2 2023 | $160,082 | -78.4% | 89,431 | -53.1% | 0.00% | – |
| Q1 2023 | $742,000 | +14622.2% | 190,668 | -87.1% | 0.00% | -100.0% |
| Q4 2022 | $5,040 | -99.5% | 1,482,164 | +727.0% | 0.00% | – |
| Q3 2022 | $978,000 | +17.8% | 179,227 | -2.7% | 0.00% | – |
| Q2 2022 | $830,000 | -84.3% | 184,165 | -74.4% | 0.00% | -100.0% |
| Q1 2022 | $5,297,000 | +10.8% | 718,640 | -3.3% | 0.00% | 0.0% |
| Q4 2021 | $4,779,000 | +76.7% | 743,400 | +59.9% | 0.00% | – |
| Q3 2021 | $2,705,000 | -45.7% | 464,921 | -3.8% | 0.00% | -100.0% |
| Q2 2021 | $4,986,000 | +39.5% | 483,222 | +42.2% | 0.00% | – |
| Q1 2021 | $3,575,000 | -31.1% | 339,747 | +1.4% | 0.00% | -100.0% |
| Q4 2020 | $5,186,000 | +11.5% | 334,978 | +5.0% | 0.00% | 0.0% |
| Q3 2020 | $4,653,000 | -9.4% | 318,985 | +17.6% | 0.00% | 0.0% |
| Q2 2020 | $5,136,000 | +3.7% | 271,180 | +5.2% | 0.00% | 0.0% |
| Q1 2020 | $4,951,000 | -27.8% | 257,725 | -27.9% | 0.00% | 0.0% |
| Q4 2019 | $6,853,000 | +231.9% | 357,487 | +66.5% | 0.00% | – |
| Q3 2019 | $2,065,000 | +64.1% | 214,713 | +4.6% | 0.00% | – |
| Q2 2019 | $1,258,000 | +3.3% | 205,264 | -1.6% | 0.00% | – |
| Q1 2019 | $1,218,000 | +10.6% | 208,527 | +77.5% | 0.00% | – |
| Q4 2018 | $1,101,000 | -46.9% | 117,483 | -3.6% | 0.00% | – |
| Q3 2018 | $2,075,000 | +0.5% | 121,829 | +0.2% | 0.00% | – |
| Q2 2018 | $2,065,000 | -46.8% | 121,544 | -58.0% | 0.00% | -100.0% |
| Q1 2018 | $3,883,000 | +35.2% | 289,367 | -3.3% | 0.00% | 0.0% |
| Q4 2017 | $2,873,000 | -14.0% | 299,293 | -2.6% | 0.00% | 0.0% |
| Q3 2017 | $3,342,000 | +925.2% | 307,200 | +753.5% | 0.00% | – |
| Q2 2017 | $326,000 | -95.1% | 35,992 | -93.1% | 0.00% | -100.0% |
| Q1 2017 | $6,660,000 | +71.8% | 518,610 | +25.8% | 0.00% | +100.0% |
| Q4 2016 | $3,877,000 | +6.5% | 412,376 | +10.3% | 0.00% | 0.0% |
| Q3 2016 | $3,639,000 | +49.9% | 374,000 | +3.3% | 0.00% | 0.0% |
| Q2 2016 | $2,428,000 | -2.9% | 361,979 | +29.2% | 0.00% | 0.0% |
| Q1 2016 | $2,500,000 | -13.1% | 280,206 | +29.0% | 0.00% | 0.0% |
| Q4 2015 | $2,878,000 | +240.2% | 217,237 | +170.1% | 0.00% | – |
| Q3 2015 | $846,000 | -63.0% | 80,438 | -4.3% | 0.00% | -100.0% |
| Q2 2015 | $2,287,000 | +57.3% | 84,076 | +77.0% | 0.00% | – |
| Q1 2015 | $1,454,000 | -22.0% | 47,505 | -4.6% | 0.00% | – |
| Q4 2014 | $1,864,000 | -2.2% | 49,800 | -8.7% | 0.00% | – |
| Q3 2014 | $1,906,000 | -23.2% | 54,550 | +2.3% | 0.00% | -100.0% |
| Q2 2014 | $2,483,000 | +12.5% | 53,325 | -25.4% | 0.00% | 0.0% |
| Q1 2014 | $2,207,000 | -11.3% | 71,450 | -34.2% | 0.00% | 0.0% |
| Q4 2013 | $2,489,000 | – | 108,591 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |